Improvement of Halitosis by Probiotic Bacterium CMU: A Randomized Controlled Trial
Overview
Affiliations
Several and studies have evaluated the effect of probiotics on oral health; however, human clinical studies are still limited. Therefore, this study aimed to examine the effects of Chonnam Medical University (CMU)-containing tablets on halitosis. This randomized, double-blinded, placebo-controlled study included 100 adults with halitosis (age, 20-70 years). The participants were randomly assigned to the test group ( = 50) and control group ( = 50). One tablet [1 × 10 colony forming units (CFU)/tablet] was to be taken each day over 8 weeks. The concentrations of volatile sulfur compounds (VSCs), bad breath improvement scores, and oral colonization of were measured. Psychosocial indicators including depression, self-esteem, oral health-related quality of life, and subjective oral health status were evaluated. Most variables were assessed at baseline, 4, and 8 weeks, and number and safety variables were assessed at baseline and 8 weeks. Intergroup comparisons were carried out using Student's -test, Chi-square test, or Fisher's exact test on per-protocol analysis. Intragroup differences before and after intake were analyzed using the linear mixed-effect model (LMM). Per-protocol analysis was carried out in the test group ( = 45) and control group ( = 46). Total VSC was significantly lower in the probiotics group than in the placebo group at baseline (week 0, = 0.046) and at 8 weeks ( = 0.017). The sum of hydrogen sulfide and methyl mercaptan did not differ significantly between the groups at baseline; however, it was significantly lower in the probiotics group than in the placebo group at week 8 ( = 0.012). Bad breath improvement (BBI) scores were significantly reduced at week 8 ( = 0.006) in the probiotics group. Statistically significant intergroup differences were observed for changes in the level of at week 8 ( < 0.001). Psychological indicators significantly improved from baseline to week 8 in the probiotics group. No safety issues were observed in either group. The levels of was higher in patients with halitosis using CMU-containing tablets. The subjective degree of bad breath and psychological indicators were improved in patients with halitosis using CMU-containing tablets.
Preventive effects of CMU on the progression of periodontitis in a rat model.
Do K, Boo S, You R, Kim S, Kim S, Seo K J Oral Microbiol. 2025; 17(1):2469895.
PMID: 40007939 PMC: 11852240. DOI: 10.1080/20002297.2025.2469895.
Probiotics for oral health: a critical evaluation of bacterial strains.
Beattie R Front Microbiol. 2024; 15:1430810.
PMID: 38979537 PMC: 11228166. DOI: 10.3389/fmicb.2024.1430810.
Petrariu O, Czobor Barbu I, Niculescu A, Constantin M, Grigore G, Cristian R Front Microbiol. 2024; 14:1296447.
PMID: 38249451 PMC: 10797027. DOI: 10.3389/fmicb.2023.1296447.
The and genera: up-to-date taxonomy, ecology, safety, biotechnological, and probiotic potential.
Fusco V, Chieffi D, Fanelli F, Montemurro M, Rizzello C, Franz C Front Microbiol. 2024; 14:1289937.
PMID: 38169702 PMC: 10758620. DOI: 10.3389/fmicb.2023.1289937.
Halitosis: etiology, prevention, and the role of microbiota.
Li Z, Li J, Fu R, Liu J, Wen X, Zhang L Clin Oral Investig. 2023; 27(11):6383-6393.
PMID: 37843633 DOI: 10.1007/s00784-023-05292-9.